Inclusion Criteria:

- Patient has a histologically-confirmed metastatic or locally advanced solid tumor
that has failed to respond to standard therapy, progressed despite standard therapy
or for which standard therapy does not exist

- Patient has life expectancy of greater than 3 months

- Patient is able to swallow capsules

Exclusion Criteria:

- Patient has had chemotherapy, radiotherapy or biological therapy 2 weeks prior to
taking study drug

- Patient is currently participating or has participated in a study with an
investigational compound or device within 30 days of signing informed consent

- Patient has active CNS metastases and/or carcinomatous meningitis

- Patient has primary central nervous system tumor

- Patient has a history of drug or alcohol abuse

- Patient has Hepatitis B or C

- Patient is HIV positive

- Patient has active infection or has received intravenous antibiotics, antiviral or
antifungal agents 2 weeks before taking study drug